NCT06293729View on ClinicalTrials.gov

Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 1, 2029

Conditions
Refractory HypercholesterolemiaFamilial Hypercholesterolemia
Interventions
DRUG

NGGT006

Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).

All Listed Sponsors
lead

Suzhou Municipal Hospital

OTHER

NCT06293729 - Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients | Biotech Hunter | Biotech Hunter